@article{c6497a6dd1a84843a9bf6c23a96c13f5,
title = "Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature",
author = "{on behalf of Precision Liver Cancer Prevention Consortium} and Atsushi Ono and Nicolas Goossens and Finn, {Richard S.} and Schmidt, {Warren N.} and Thung, {Swan N.} and Im, {Gene Y.} and Yujin Hoshida",
note = "Funding Information: Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29203 Potential conflict of interest: Dr. Finn consults for Bayer, Pfizer, Bristol-Myers Squibb, Novartis, and Eisai. Dr. Ono received grants from Bristol-Myers Squibb. Funding Information: Received January 24, 2017; accepted April 5, 2017. Supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (DK099558), the European Union (ERC-2014-AdG-671231HEPCIR), the Irma T. Hirschl Trust, the US Department of Defense (W81XWH-16-1-0363, to Y.H.), and the National Institutes of Health Loan Repayment Program (to G.Y.I.).",
year = "2017",
month = oct,
doi = "10.1002/hep.29203",
language = "English",
volume = "66",
pages = "1344--1346",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",
}